About Us
Our Product Pipeline

Developing scalable Cell replacement therapies to treat incurable diseases for the world.

Our Market

We intend to be the benchmark for quality and affordability in cells therapies for our targeted conditions and expect to capture 1/6th of each of the following global markets:

Dry AMD~ USD 72 bn.
Retinitis Pigmentosa~ USD 10 bn.
Idiopathic Pulmonary Fibrosis~ USD 20 bn.
Product Indication In vitro studies Proof-of-concept animal studies GLP tox, safety and efficacy First in Human trials
Eyecyte-RPETM Geographic Atrophy
Eyecyte-PRPTM Retinitis Pigmentosa
Aircyte-AEC Idiopathic Pulmonary Fibrosis
Neural Progenitor Cells Parkinson’s Disease
AAV- mediated gene augmentation platform Inherited Retinal Dystrophies

RPE cells – Phase

RPE cells – Immunocytochemistry

Our Lead Asset

Eyecyte-RPETM replaces lost retinal pigment epithelium cells. It is designed to restore sight for patients in the early stages of Age-Related Macular Degeneration and arrest losses for those in the later stages.

The product is allogenic and administered by sub-retinal injection.
Application for first in human trials with the Indian regulatory authorities is scheduled for Q2, 2023.

We are one of six players globally developing this solution.

Our Other Assets

Eyecyte-PRPTM replaces lost photoreceptor cells. It is proven in treating Retinitis Pigmentosa in animals. Extensive animal testing is scheduled to begin in the second half of 2023 with an aim to move this product into clinical stage in second half of 2024.

We are one of five players globally developing this solution.

PRP cells – Phase

PRP cells – Immunocytochemistry

Aircyte-AEC restore lung function for patients suffering from Idiopathic Pulmonary Fibrosis. The product is delivered to the alveolar surfaces by an intra-bronchial inhalation. Proof of concept demonstration of animal efficacy has been done and the product will soon enter extensive animal testing.

We are the leading global player developing this solution.

Lung epithelial cells – Phase

Lung epithelial cells – Immunocytochemistry